Zoetis Inc. (NYSE:ZTS) Stock Holdings Increased by Premier Fund Managers Ltd

Premier Fund Managers Ltd raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 5.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 56,258 shares of the company’s stock after buying an additional 2,700 shares during the quarter. Premier Fund Managers Ltd’s holdings in Zoetis were worth $10,956,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. First Personal Financial Services acquired a new stake in shares of Zoetis during the 3rd quarter valued at approximately $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis during the third quarter worth $33,000. Quarry LP lifted its position in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the last quarter. Fortitude Family Office LLC lifted its position in shares of Zoetis by 1,387.5% in the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after buying an additional 222 shares during the last quarter. Finally, LRI Investments LLC acquired a new position in shares of Zoetis in the 1st quarter valued at about $43,000. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ZTS. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Stifel Nicolaus boosted their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. upped their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Trading Down 0.5 %

NYSE:ZTS opened at $175.57 on Wednesday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The business has a fifty day moving average of $186.47 and a 200-day moving average of $180.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a market cap of $79.21 billion, a price-to-earnings ratio of 33.00, a PEG ratio of 2.71 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.36 EPS. Equities analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be given a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. Zoetis’s dividend payout ratio (DPR) is 32.52%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.